Professor Jeremy Chataway MA, PhD, FRCP Consultant Neurologist/Reader in Neurology: National Hospital for Neurology and Neurosurgery, Queen Square, University College Foundation NHS Trust, UCL, London.
After qualifying in medicine at Cambridge and Oxford Universities, and general medical training in London, Professor Chataway specialised in Neurology over an 8 year period with posts in Edinburgh, Cambridge and London. He was awarded a PhD from Cambridge University in genetic epidemiology of multiple sclerosis (MS) and took up his post as a consultant Neurologist in 2001 at St Mary’s Hospital and The National Hospital for Neurology and Neurosurgery, Queen Square. At St Mary’s Hospital he was involved in the full range of general neurology in both inpatient and outpatient settings. He was heavily involved in setting up and running the stroke unit. He is now full time at the National Hospital, Queen Square where he is the MS clinical lead.
In 2012 he had the honour to be the Chief Neurologist to the Olympic Games in London. He is also neurologist to St Luke’s for the Church of England.
His private practice is in all aspects of general neurology including: headache and migraine; stroke and TIA; epilepsy; multiple sclerosis; Parkinson’s disease and neuropathies. He is able to perform botulinum toxin injections for spasticity and tremor.
His private practice at the Hospital of St John and St Elizabeth and Highgate Hospital offer the full range of modern imaging (CT and MRI); electrophysiology (Nerve conduction and EMG) and ultrasound (Doppler). There is also easy access to consultants in other specialities.
In view of his particular interest in MS, he offers a dedicated service involving all aspects of diagnosis, choice of disease modifying treatment/switching, and symptomatic control. He also works closely with the neuro-radiology department for MRI review and analysis.There is a fully integrated multi-disciplinary therapy (MDT) approach with colleagues particularly in neuro-physiotherapy/occupational therapy.
This is now centred on multiple sclerosis and based at the National Hospital for Neurology and Neurosurgery, Queen Square, UCLH. He is particularly involved in clinical trials and service developments in MS at Queen Square. He is entirely familiar with all advanced disease modifying treatments including: beta-interferons, tecfidera, fingolimod, alemtuzumab and natalizumab.
He co-leads the Adult onset Leukodystrophy Group (ALG).
Professor Chataway is a Reader in Neurology at University College London. He is particularly interested in treatment trials in multiple sclerosis, and especially progressive MS. He was the Chief Investigator (CI) of the MS-STAT trial of high dose simvastatin in secondary progressive MS (SPMS) reported in the Lancet in 2014. Link to paper. He is currently the CI of the currently enrolling MS-SMART trial in SPMS.
He was a member of the recently reported NICE review into MS link. He sits on a number of committees for the UK MS society. He is the newly appointed Clinical Director of the UCL Comprehensive Clinical Trials Unit.
For research enquiries contact Marie Braisher: email@example.com